Urinary inositol phosphoglycan P-type as a marker for prediction of preeclampsia and novel implications for the pathophysiology of this disorder

Hypertension in Pregnancy

Volumn 29, Issue 4, 2010, Pages 375-384

  Paine, Malcolm A ^a   Scioscia, Marco ^a,b   Williams, Philip J ^a   Gumaa, Khalid ^c   Rodeck, Charles H ^a   Rademacher, Thomas W ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^c ARABIAN GULF UNIVERSITY   (Bahrain)

Author keywords

Abnormal stimulus; Inositol phosphoglycan; Insulin resistance; Preeclampsia; Screening test

Indexed keywords

INOSITOL PHOSPHOGLYCAN P; PHOSPHOLIPID DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK PREGNANCY; HUMAN; LONGITUDINAL STUDY; MATERNAL HYPERTENSION; PATHOPHYSIOLOGY; PREDICTION; PREECLAMPSIA; PREGNANCY; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SCREENING TEST; SENSITIVITY AND SPECIFICITY; URINALYSIS; URINARY EXCRETION;

ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INOSITOL PHOSPHATES; POLYSACCHARIDES; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY, HIGH-RISK; PROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 77957310222     PISSN: 10641955     EISSN: 15256065     Source Type: Journal    
DOI: 10.3109/10641950903242667     Document Type: Article

References (29)

1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785-799.
2. Ness RB, Roberts JM. Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. Am J Obstet Gynecol 1996;175:1365-1370.
3. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000;183: S1-S22.
4. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003;102:181-192.
5. Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004;104:1367-1391.
6. Kunjara S, Greenbaum AL, Wang DY, et al. Inositol phosphoglycans and signal transduction systems in pregnancy in preeclampsia and diabetes: evidence for a significant regulatory role in preeclampsia at placental and systemic levels. Mol Genet Metab 2000;69:144-158.
7. Paine MA, Scioscia M, Gumaa KA, Rodeck CH, Rademacher TW. P-type inositol phosphoglycans in serum and amniotic fluid in active pre-eclampsia. J Reprod Immunol 2006;69:165-179.
8. Rademacher TW, Caro H, Kunjara S, Wang DY, Greenbaum AL, McLean P. Inositolphosphoglycan second messengers. Braz J Med Biol Res 1994;27:327-341.
9. Scioscia M, Gumaa K, Whitten M, Selvaggi LE, Rodeck CH, Rademacher TW. Inositol phosphoglycan P-type in healthy and preeclamptic pregnancies. J Reprod Immunol 2007;76:85-90. (Pubitemid 350100880)
10. Rademacher TW, Gumaa K, Scioscia M. Preeclampsia, insulin signalling and immunological dysfunction: A fetal, maternal or placental disorder? J Reprod Immunol 2007;76:78-94.
11. Williams PJ, Gumaa K, Scioscia M, Redman CW, Rademacher TW. Inositol phosphoglycan P-type in preeclampsia: a novel marker? Hypertension 2007;49:84-89. (Pubitemid 46360345)
12. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005;330:565.
13. Varela-Nieto I, Leon Y, Caro HN. Cell signalling by inositol phosphoglycans from different species. Comp Biochem Physiol B Biochem Mol Biol 1996;115:223-241.
14. Barton JR, Istwan NB, Rhea D, Collins A, Stanziano GJ. Cost-savings analysis of an outpatient management program for women with pregnancy-related hypertensive conditions. Dis Manag 2006;9:236-241.
15. Grimes DA, Schulz KF. Uses and abuses of screening tests. Lancet 2002;359:881-884.
16. Grimes DA, Schulz KF. Refining clinical diagnosis with likelihood ratios. Lancet 2005;365:1500-1505.
17. Paine MA, Rodeck CH, Williams PJ, Rademacher TW. Possible involvement of inositol phosphoglycan-P in human parturition. J Reprod Immunol 2003;59:267-275.
18. Myatt L, Miodovnik M. Prediction of preeclampsia. Semin Perinatol 1999;23:45-57.
19. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005;308:1592-1594.
20. Robillard PY, Hulsey TC. Association of pregnancy-induced-hypertension, pre-eclampsia, and eclampsia with duration of sexual cohabitation before conception. Lancet 1996;347:619.
21. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-454.
22. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006;116:1793-1801.
23. Kaaja R, Laivuori H, Laakso M, Tikkanen MJ, Ylikorkala O. Evidence of a state of increased insulin resistance in preeclampsia. Metabolism 1999;48:892-896.
24. Martinez AE, Gonzalez OM, Quinones GA, Ferrannini E. Hyperinsulinemia in glucosetolerant women with preeclampsia. A controlled study. Am J Hypertens 1996;9:610-614.
25. Scioscia M, Gumaa K, Kunjara S, et al. Insulin resistance in human preeclamptic placenta is mediated by serine phosphorylation of insulin receptor substrate-1 and-2. J Clin Endocrinol Metab 2006;91:709-717.
26. Saito S, Sakai M. Th1/Th2 balance in preeclampsia. J Reprod Immunol 2003;59:161-173.
27. Scioscia M, Vimercati A, Selvaggi LE, Rodeck CH, Rademacher TW. Inositol phosphoglycan putative insulin mediator in human amniotic fluid. J Matern Fetal Neonatal Med 2006;19:9-12.
28. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006;113:1888-1904.
29. Cywinski J. The essentials in pressure monitoring. Martinus Nijhoff Publishers: Boston, 1980;23-24.